الانتقال إلى المحتوى الرئيسي
xMedica

NCT05491525ClinicalTrials.gov

Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC

A Phase 2/3, Open-label, Baseline-controlled, Multicenter, Long-term Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With Neurogenic Detrusor Overactivity (NDO) on Clean Intermittent Catheterization (CIC)

قيد التجنيديقبل مشاركين الآن، وفقاً لسجل السجل.
التواصل مع هذه الدراسة

باختصار

The purpose of this study is to evaluate the safety, efficacy, and PK of Vibegron in pediatric participants with NDO who are regularly using CIC

المرحلة 2 / المرحلة 3مطلوب 71 مشاركاً38 موقعاً16 دولة

الفئات

مسجَّلة في سجل واحد

يمكن أن تُسجَّل دراسة واحدة في عدة سجلات. نعرضها مرة واحدة ونربط بكل سجل نحتفظ به.

تُعرض معلومات التجربة كما نشرها السجل، بلغتها الأصلية.

هل أنت مهتم بهذه الدراسة؟

تسجيل الدخول أو أنشئ حسابًا لتسجيل اهتمامك ومتابعة هذه الدراسة.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Present: Registered before enrolment beganFirst posted 2022-08-08; recorded start 2022-10-12
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Not stated: Participants are not randomly assignedAllocation is recorded as non-randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Not stated: Open label (no blinding)Masking is recorded as none (open label)
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Not stated: No other studies from this sponsor are in this databaseCounted from the lead sponsor named in the record (Urovant Sciences GmbH)
  • Not stated: No posted results from this sponsor are in this database yetBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourEXPLORATORY

An exploratory-stage design for a phase 3 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation0/20

    Non-randomised allocation

  • Blinding0/20

    Open-label

  • Control arm0/15

    No comparator arm stated in the record

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre8/8

    Multi-centre: 38 sites

  • Data monitoring committee7/7

    A data monitoring committee is in place

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleSMALL

A small study, international in scope: 71 participants (target), run at 38 sites, across 16 countries.

How this score is built
  • Enrolment17/40

    71 participants (target)

  • Site count19/25

    38 sites

  • Country count15/15

    16 countries

  • Planned duration10/10

    Planned over about 96 months

  • Sponsor scale0/10

    Urovant Sciences GmbH has led 1 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

ملخص

The purpose of this study is to evaluate the safety, efficacy, and PK of Vibegron in pediatric participants with NDO who are regularly using CIC

الحالات

  • Neurogenic Detrusor Overactivity

الأهلية

الأهلية
الجنسالجميع
الأعمار2 Years17 Years
المتطوعون الأصحّاءلا

الأهلية كما كُتبت في السجل

Inclusion Criteria: * Male or female participants, age 2 years to \< 18 years and weighing at least 11 kg at the Screening Visit. * Participant has been diagnosed with NDO due to one of the following: spinal dysraphism, which includes spina bifida (eg, myelomeningocele, meningocele) and all forms of tethered cord; or acquired NDO from a spinal cord injury or spinal cord surgery, with the injury/surgery having occurred at least 6 months prior to the Screening Visit; or acquired NDO due to transverse myelitis with diagnosis at least 12 months prior to the Screening Visit. * Participant undergoes CIC at least 3 times per 24 hours (with the last CIC performed prior to going to sleep for the night) for at least 4 weeks prior to the Screening Visit. Exclusion Criteria: * Participant has cerebral palsy, uncontrolled epilepsy, diabetes insipidus, or Stage 2 hypertension * Participant has an active malignancy in the 12 months prior to the Screening Visit. * Participant has been administered intravesical botulinum toxin within 9 months prior to the Screening Visit and should remain off this therapy during the study. * Participant is taking digoxin or lithium within 10 days prior to Screening Visit or plans to start taking either during the study. * Participant currently uses or plans to use a baclofen pump during the study. * Participant has had urethral dilatation or urethral surgery in the 3 months prior to the Screening Visit. * Participant has undergone bladder augmentation surgery. * Participant has a known genitourinary condition (other than NDO) that may cause overactive contractions or incontinence (bladder exstrophy, urinary tract obstruction, urethral diverticulum or fistula) or bladder stones or another persistent urinary tract pathology that may cause symptoms. * Participant has an insufficient urethral sphincter, has had implantation of an artificial sphincter, has a surgically-treated underactive urethral sphincter, or, in the 6 months prior to the Screening Visit, has undergone pelvic gender reassignment surgery. * Participant has one of the following gastrointestinal problems: partial or complete obstruction, decreased motility such as paralytic ileus, risk of gastric retention, or malabsorption syndrome of any form. * Participant has acute fecal impaction or, within the 3 months prior to the Screening Visit, had fecal impaction that required hospitalization or ambulatory surgical treatment. * Participant had a urinary indwelling catheter in the 4 weeks prior to the Screening Visit. * Participant has moderate to severe dilating vesicoureteral reflux (Grade IV to V) or severe renal failure. * Participant started electrostimulation/neuromodulation therapy in the 4 weeks before the Screening Visit, or is expected to start this therapy during the study period. * Participant has participated in another clinical trial and/or has taken an investigational drug within 4 weeks prior to the Screening Visit. * Participant is unable, or parent/caregiver is not willing, to washout any medication for the management of NDO. * Participant is a female of childbearing potential who is unwilling or unable to use a highly effective method of contraception for the duration of the study. * Female participants who are currently breastfeeding or plan to breastfeed any time from the Screening Visit until 28 days after the final study drug administration.

الأهلية في عبارات بسيطة

لم تُقسَّم معايير هذا السجل إلى عبارات منفصلة بعد. نص السجل أعلاه كامل وهو النسخة المُعتمَدة.

تصميم الدراسة

تصميم الدراسة
نوع الدراسةتدخّلية
المرحلةالمرحلة 2 / المرحلة 3
التخصيصغير معشّاة
نموذج التدخّلPARALLEL
الغرض الأساسيTREATMENT
التعميةNONE (0)
التجنيدمطلوب 71 مشاركاً

الجهة الراعية والمتعاونون

  • Urovant Sciences GmbH الجهة الراعية
  • Sumitomo Pharma America, Inc. المتعاونون

الأذرع والتدخلات

  • Cohort 1: Weight >=41.5kgEXPERIMENTAL

    Part A: Participants will receive a dose of Vibegron based on their weight, with dose reduction based on individual clinical condition, PK, and safety/tolerability data. Participants may be dose-reduced up to 2 times. Part B: Participants will receive a Data and Safety Monitoring Board (DSMB)-selected Vibegron dose for their weight determined from participants in their respective cohort and weight band of Part A.

  • Cohort 2: Weight Range >=29.5 kg to <=41.4 kgEXPERIMENTAL

    Part A: participants will receive a dose of Vibegron based on their weight, with dose reduction based on individual clinical condition, PK, and safety/tolerability data. Participants may be dose-reduced up to 2 times. Part B: Participants will receive a DSMB-selected Vibegron dose for their weight determined from participants in their respective cohort and weight band of Part A.

  • Cohort 3: Weight range >=11 kg to <=29.4 kgEXPERIMENTAL

    Part A: Participants will receive a dose of Vibegron based on their weight, with dose reduction based on individual clinical condition, PK, and safety/tolerability data. Participants may be dose-reduced up to 2 times. Part B: Participants will receive a DSMB-selected Vibegron dose for their weight determined from participants in their respective cohort and weight band of Part A.

التدخلات

  • دواء Vibegron

    Participants will be administered Vibegron orally, once daily (QD)

مقاييس النتائج

  1. مقياس النتيجة الأولي

    Change from Baseline in maximum cystometric capacity (MCC) based on bladder filling urodynamics

    الإطار الزمني Optimized Treatment Week 24

  2. مقياس النتيجة الثانوي

    Change from Baseline in MCC

    الإطار الزمني Optimized Week 12

  3. مقياس النتيجة الثانوي

    Change from Baseline in number of overactive detrusor contractions until the end of bladder filling

    الإطار الزمني Optimized Treatment Weeks 12 and 24

  4. مقياس النتيجة الثانوي

    Change from Baseline in detrusor pressure at the end of bladder filling

    الإطار الزمني Optimized Treatment Weeks 12 and 24

  5. مقياس النتيجة الثانوي

    Change from Baseline in bladder filling volume until first involuntary/hyperactive detrusor contraction

    الإطار الزمني Optimized Treatment Weeks 12 and 24

  6. مقياس النتيجة الثانوي

    Change from Baseline in bladder compliance (mL/cm H2O)

    Bladder compliance is calculated by dividing the change in volume by the change in detrusor pressure during the filling of the bladder

    الإطار الزمني Optimized Treatment Weeks 12 and 24

  7. مقياس النتيجة الثانوي

    Change from Baseline in average first morning catheterized volume

    الإطار الزمني through study completion, an average of 52 weeks

  8. مقياس النتيجة الثانوي

    Change from Baseline in average catheterized volume per catheterization

    الإطار الزمني through study completion, an average of 52 weeks

  9. مقياس النتيجة الثانوي

    Change from Baseline in average maximum catheterized volume per day

    الإطار الزمني through study completion, an average of 52 weeks

  10. مقياس النتيجة الثانوي

    Change from Baseline in average maximum catheterized daytime volume

    الإطار الزمني through study completion, an average of 52 weeks

  11. مقياس النتيجة الثانوي

    Change from Baseline in average number of leakage episodes per day

    الإطار الزمني through study completion, an average of 52 weeks

  12. مقياس النتيجة الثانوي

    Change from Baseline in estimated number of dry (leakage-free) days/ 7 days

    الإطار الزمني through study completion, an average of 52 weeks

  13. مقياس النتيجة الثانوي

    Change from Baseline in Pediatric Incontinence Questionnaire (PIN-Q)

    PIN-Q is a 20-item questionnaire addressing quality of life for participants with bladder disorders. Each question was answered on a scale from 0 (no, never) to 4 (all the time). The total score ranged from 0 to 80, with higher scores indicating more impact on the quality of life.

    الإطار الزمني through study completion, an average of 52 weeks

  14. مقياس النتيجة الثانوي

    Change from Baseline in Patient Global Impression of Severity (PGI-S) Scale

    PGI-S is a 5 point scale that determines the bladder condition of a participant with 0 being really bad and 4 as really good. Higher score indicates better bladder condition.

    الإطار الزمني through study completion, an average of 52 weeks

  15. مقياس النتيجة الثانوي

    Change from Baseline in Clinical Global Impression of Change (CGI-C) Scale

    The CGI-C scale is used to determine the degree of change in participant's overall bladder symptoms since the start of the study on Day 1. The scale will be filled by the investigator by ticking on any of the following options: very much improved, much improved, minimally improved, no change, minimally worse, much worse and very much worse.

    الإطار الزمني through study completion, an average of 52 weeks

التواريخ

التواريخ
تاريخ البدء12 أكتوبر 2022 (فعلي)
الإتمام الأولي1 مارس 2030 (تقديري)
الإتمام1 سبتمبر 2030 (تقديري)
أول نشر8 أغسطس 2022 (فعلي)
آخر تحديث15 يونيو 2026
النتائج منشورةغير مذكور في سجل السجل
آخر تأكيد للحالةيونيو 2026

فعلي يعني أن الحدث وقع. تقديري يعني أن الجهة الراعية تتوقعه. للكلمتين معنيان مختلفان.

المواقع

32 موقعاً قيد التجنيد

Belgium

Belgium
المنشأةالمدينةالولاية أو المنطقةالحالة
Universitair Ziekenhuis AntwerpenEdegemAntwerpenمسحوب
UZ GentGhentEast Flandersقيد التجنيد

Canada

Canada
المنشأةالمدينةالولاية أو المنطقةالحالة
Alberta Children's HospitalCalgaryAlbertaقيد التجنيد
The Hospital for Sick ChildrenTorontoOntarioقيد التجنيد

Croatia

Croatia
المنشأةالمدينةالولاية أو المنطقةالحالة
University Hospital Split - KBC SplitSplitقيد التجنيد

Denmark

Denmark
المنشأةالمدينةالولاية أو المنطقةالحالة
Aarhus University Hospital - Department of Paediatrics and Adolescent MedicineAarhusقيد التجنيد

Georgia

Georgia
المنشأةالمدينةالولاية أو المنطقةالحالة
JSC Evex Hospital M. lashvili Childrens Central HospitalTbilisiقيد التجنيد

Jordan

Jordan
المنشأةالمدينةالولاية أو المنطقةالحالة
Jordan University HospitalAmmanقيد التجنيد
Istiklal HospitalAmmanقيد التجنيد
Irbid Specialty HospitalIrbidقيد التجنيد

Latvia

Latvia
المنشأةالمدينةالولاية أو المنطقةالحالة
Childrens Clinical University HospitalRigaمسحوب

Lithuania

Lithuania
المنشأةالمدينةالولاية أو المنطقةالحالة
Hospital of Lithuanian University of Health Sciences Kauno klinikosKaunasقيد التجنيد
Vilnius University Hospital Santaros KlinikosVilniusقيد التجنيد

Malaysia

Malaysia
المنشأةالمدينةالولاية أو المنطقةالحالة
Kuala Lumpur HospitalKuala LumpurKuala Lumpurقيد التجنيد
Hospital Umum SarawakKuchingSarawakقيد التجنيد

Philippines

Philippines
المنشأةالمدينةالولاية أو المنطقةالحالة
National Children's HospitalQuezon CityNational Capital Regionقيد التجنيد

Poland

Poland
المنشأةالمدينةالولاية أو المنطقةالحالة
Uniwersytecki Dzieciecy Szpital Kliniczny im. L. ZamenhofaBialystokقيد التجنيد
Uniwersyteckie Centrum KliniczneGdanskقيد التجنيد
Instytut Pomnik - Centrum Zdrowia DzieckaWarsawقيد التجنيد

Romania

Romania
المنشأةالمدينةالولاية أو المنطقةالحالة
Institutul Clinic FundeniBucharestBucharestقيد التجنيد
Maria Sklodowska Curie Childrens Clinical Emergency HospitalBucharestBucharestقيد التجنيد

Serbia

Serbia
المنشأةالمدينةالولاية أو المنطقةالحالة
University Children's Hospital TirsovaBelgradeقيد التجنيد
Children and Youth Health Care Institute of VojvodinaNovi Sadقيد التجنيد

Slovakia

Slovakia
المنشأةالمدينةالولاية أو المنطقةالحالة
Detská fakultná nemocnica s poliklinikou/Národný ústav detských chorôb (NÚDCH)Bratislavaقيد التجنيد
Urologická ambulancia J. BREZA MEDICAL s.r.o.Bratislavaقيد التجنيد

Turkey (Türkiye)

Turkey (Türkiye)
المنشأةالمدينةالولاية أو المنطقةالحالة
Ankara University Faculty of Medicine Ibni Sina HospitalAnkaraAltindagقيد التجنيد
Mersin University, Dept. of UrologyYenişehirقيد التجنيد

United States

United States
المنشأةالمدينةالولاية أو المنطقةالحالة
Albany Medical CollegeAlbanyNew Yorkقيد التجنيد
Children's Hospital ColoradoAuroraColoradoقيد التجنيد
Duke University Medical CenterDurhamNorth Carolinaأُنهي
Nemours Childrens Health, JacksonvilleJacksonvilleFloridaقيد التجنيد
Arkansas Childrens HospitalLittle RockArkansasقيد التجنيد
Childrens Hospital New OrleansNew OrleansLouisianaمسحوب
University of OklahomaOklahoma CityOklahomaقيد التجنيد
Children's Hospital of Orange CountyOrangeCaliforniaأُنهي
Oregon Health & Science UniversityPortlandOregonمسحوب
SUNY Upstate Medical UniversitySyracuseNew Yorkقيد التجنيد
Wichita Urology GroupWichitaKansasقيد التجنيد

مستندات الدراسة

لا تُرتبط أي مستندات في سجل السجل هذا.

التغيّرات عبر الزمن

لم تُسجَّل أي تغييرات منذ أن أدرجنا هذا السجل لأول مرة.

يُسجَّل تغيير في كل مرة تحدّث فيها الجهة الراعية سجل السجل. تظهر هنا الحالة والتواريخ والتجنيد والمواقع كلما تغيّرت.